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Our gut harbors an extremely diverse collection of trillions of microbes that, besides degrad-
ing the complex dietary constituents, execute numerous activities vital for our metabolic
and immune health. Although the importance of gut microbiota in maintaining digestive
health has long been believed, its close correlation with numerous chronic ailments has
recently been noticed, thanks to the innovative mechanistic studies on the compositional
and functional aspects of gut microbial communities using germ-free or humanized ani-
mal models. Since a myriad of mysteries about the precise structures and functions of
gut microbial communities in specific health situations still remains to be explicated, the
emerging field of gut microbiota remains a foremost objective of research for microbiolo-
gists, immunologists, computational biologists, clinicians, food and nutrition experts, etc.
Nevertheless, it is only after a comprehensive understanding of the structure, density, and
function of the gut microbiota that the new therapeutic targets could be captured and
utilized for a healthier gut as well as improved overall well-being.
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Inception: “I then most always saw, with great wonder, that in
the said matter, there were many very little living animalcules,
very prettily a-moving”.
–Antonie van Leeuwenhoek
Since 1676 when Antonie van Leeuwenhoek first observed the
dental microbiota by using his microscope, scientists from all
across the globe have always been trying vigorously to explore
the diversity and functionality of human-related microbiota. It is
now scientifically well-acknowledged that microbes living indige-
nously in or on the human body perform countless vital functions
related to nutrition, metabolism, immunity, diseases, aging, etc.,
and most of our crucial and fundamental life functions are exten-
sively dependent on our microbiome (1–5). Although extensive
literature is available now on the diversity of microbiota associ-
ated with our body system, insights into their specific implication
and contribution in various physiological functions of human
body are just in the beginning stages and there remains a wide
array of important issues to be explored and resolved in order to
completely understand the complexity of human–microbe rela-
tionships. In particular, the role of gut microbiota in health and
diseases has been one of the most vigorous and intriguing field
of recent researches, although many ambiguities still remain to be
elucidated.
Our gut harbors an immensely diverse collection of microor-
ganisms comprising about tens of trillions of microbes, com-
prising of more than 1000 diverse species of identified bacteria
with over three million genes (about 150 times more than human
genes). In addition to degrading indigestible dietary components,
the gut microbiota is also believed to possess numerous other
metabolic abilities and activities that are yet to be discovered or
interpreted. Although the gnotobiotic studies have evidenced the
significance of gut microbial communities in maintaining nor-
mal health and well-being in our life, recent investigations on
compositional alterations in gut microbial communities, partic-
ularly diet-induced, have revealed an unexpected aspect of the
alleged role of gut microbiota in the epidemics of chronic ill-
nesses such as obesity, insulin resistance, type 2 diabetes, metabolic
syndrome, inflammatory bowel disease, non-alcoholic fatty liver
diseases, atopic allergic disorders, etc. (Figure 1) (5–10). Oppor-
tunely, the recent technological advancements in gene sequenc-
ing techniques coupled with promising bioinformatics’ tools and
omics-based approaches are revolutionizing and aiding in boost-
ing up the extensive and vertical researches on various structural
as well as functional aspects of the core human gut microbiome,
thereby facilitating the exploration of diverse gut microbial com-
munities and capturing the fundamental changes associated with
gut-related ailments. Nevertheless, it is only after an exhaustive
comprehension of the diversities, complexities, and functionali-
ties of the gut microbiota that the novel therapeutic targets could
be discovered and exploited for better gut as well as overall health
(Figure 1).
Since gut microbiota keeps on evolving throughout our entire
life, varying from birth to old age, from individual to individual,
from healthy to diseased, from children to adults to elderly, etc.
(1, 9, 11–14), it is far from settled that what makes a “healthy”
or “ideal” gut microbiota profile, particularly when we do not
have a model or blueprint of an ideal baseline gut microbiota.
While about one-third of our gut microbiota is common to most
other humans, the remaining two-thirds (particularly the species
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FIGURE 1 | Speculated health implications of gut microbiota. NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; HS, hepatic
steatosis; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; UC, ulcerative colitis.
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FIGURE 2 | Importance of balanced nutrition and gut microbiota, and consequences of gut dysbiosis. MetS, metabolic syndrome; NAFLD, non-alcoholic
fatty liver disease; NASH, non-alcoholic steatohepatitis; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; CVD, cardiovascular diseases.
composition) may be specific to the individual and may vary in
response to our environmental, dietary, and lifestyle influences (7,
9, 11–15). Although ample evidences have emerged out to sup-
port the notion that gut microbiota plays an epicentral role in the
triangle of diet, health, and diseases, there still subsist a multi-
tude of hidden facts and doubts that remain to be explored and
investigated (Figure 2). Obviously, the next step to these predica-
ments shall be to define a “healthy” infant, adult, and elderly gut
microbiota. Moreover, keeping in mind the concept of healthy gut
microbiota, it needs to be elucidated what composition of diet and
types of dietary macronutrients (for instance, ratios and types of
carbohydrates, fats, proteins, etc.) shall be “ideal” to sustain this
“healthy” gut microbiota in healthy as well as in a diseased situa-
tion? (Figure 2). It does not seem to be easy, since the differences in
gut microbiota of healthy and diseased hosts are thin but very com-
plex (9, 11–13, 15). How the diet or dietary components influence
the gut microbiota and then how the gut microbiota responds and
influences the host metabolism shall be a hectic task to elucidate.
Undoubtedly, plentiful data are gradually accumulating to indicate
that the gut microbiota could significantly influence a number of
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metabolic pathways in the host nutrition, including carbohydrate,
lipids, bile acids, short-chain fatty acids, vitamins, energy extrac-
tion, fat storage, etc. (3–6, 10, 13, 15). It can easily be summed
up from these established and acknowledged facts that we share
a delicate and straight give-and-take relationship with our gut
microbiota (quote: “we give it good, it gives us good; we give it bad,
it may give us worse”). Furthermore, although numerous reports
are available to indicate the therapeutic role of dietary supple-
ments on gut microbiota-mediated health effects, more trials are
anticipated to illustrate and authenticate the mechanistic and clin-
ical influences of these supplements such as probiotics, prebiotics,
antibiotics, herbal compounds, or nutraceutical interventions on
gut microbiome and overall health (16–18). Another hurdle could
be to identify and separate out the beneficial, commensal, and
harmful microbes out of the extremely complex gut microbial
world. More particularly, identifying the beneficial, harmless, and
harmful microbes, delineating the effects of surplus beneficial bac-
teria and too less pathogenic bacteria, and then puzzling out how
much of whom is “too much” or “too less” seems to be a tricky and
laborious task, especially in view of the fact that each and every
member of the gut microbial ecosystem is significant to the overall
composition of gut microbiota makeup (14, 19, 20). Obviously, it
is only after we know the precise role of each and every member of
the gut microbial family that we could manipulate it by reducing
the harmful ones either with the beneficial ones or targeted thera-
peutics or both in order to upgrade the concept of gut microbiota
from disease predisposition to disease prevention and treatment
without affecting the metabolic and physiological health.
Although it is evident now that gut microbial alterations are
linked with several ailments (5–7, 10, 12, 13), it is still not com-
pletely explained whether gut microbial alterations produce the
disease or it is the other way around. Again, it is only after sketch-
ing out the healthy gut microbial makeup that we could imagine
prospective nutrition-based therapies intended to normalize the
altered gut microbiota to a normal one (Figure 2). Another impor-
tant link between gut microbiota and diseases is gut permeability,
and it shall be prerequisite to explicate whether altered gut micro-
biota is causing the disease or the injured gut permeability or
both, particularly in maladies associated with “leaky gut” such as
insulin resistance, type 2 diabetes, inflammatory bowel diseases,
irritable bowel syndrome, celiac diseases, etc. (Figure 2) (7). The
new concept of fecal transplant is also in unsteady status, and is
going to be tested further in animal as well as clinical settings.
Another common question which needs to be addressed com-
prehensively is whether 1 g of fecal sample could truly represent
the gut microbiota, since the flora of lower intestinal sample may
differ (slightly or largely) from that of actual intestinal environ-
ment. In addition, there is a variation in the microbial diversity
in distal colon to that in upper gut or other parts of the large
intestine. Moreover, there might be some variation in the bacterial
relative abundance within one sample but at different sampling
spots. Also, using the gut microbiota signature for diagnosis and
targeting it for prevention as well as treatment of an ailment
such as obesity, insulin resistance, metabolic syndrome, type 2
diabetes, hepatic steatosis, bowel diseases, etc., needs to be expli-
cated further. The relationship between infant’s and mother’s gut
microbiota still remains ambiguous, and needs to be verified in
healthy as well as abnormal settings, in addition to the effect of
mother’s vaginal microflora and milk components such as fatty
acids and hormones on infants gut microbial health. Also, how the
gut microbiota at-birth relates to the health and disease predispo-
sition during later years seems to be intriguing (9). Nonetheless,
with the advent of advanced next-gen sequencing tools and tech-
nologies and rigorous progresses in mechanistic studies of the
human microbiome project via gut microbiome, metagenome,
metatranscriptome, metaproteome, metabolome, inflammasome,
etc., these doubts and challenges are appearing to be deciphered
more quickly than expected in near future (14, 19–21).
Though, the research on human gut microbiota is succeeding
logarithmically, the field still remains an emerging and in-progress
area of research. Our gut microbiome includes more than three
million genes, however, we do not know much about the func-
tions or interactions of most of these genes (20). Investigators
are making incredible advances in comprehending not just what
the gut microbiota does or can do, but also how these microbes
do whatever they do, how this mystifying group of gut microbes
could positively and negatively impact our nutrition, physiology,
healthiness, and diseases, and how can we can manipulate or engi-
neer it for better clinical health. Certainly, it can easily be envisaged
that this evolution of research on gut microbiota shall revolution-
ize the notion of “we are what we eat” to “we are what our gut
microbiome is.” Optimistically, we may soon witness an era where
the gut microbiome clinics shall be prevalent all around and the
individual’s gut microflora will be widely used as a diagnostic,
prophylactic as well as therapeutic target for a myriad of health
problems, and more fascinatingly, the gut microbiome at infant
stage shall be used to predict predisposition to numerous ailments
in later years, and individuals’ diet regimens shall be designed
exclusively according to their gut microbiota profile for a better
and disease-free health and well-being. In the meantime, in all this
evolving setting, the practicing clinicians, so far excluded by any
objective understanding of gut milieu changes, are receiving ample
help from a number of reliable and precise non-invasive diagnos-
tic tools to scrutinize gut microbiota, dysbiosis, gut inflammation,
and gut permeability which is proving to be valuable in clini-
cal practice to unveil subtle disease risk-prone conditions, shape
up a tentative-tailored intervention, and maintain an objective
follow-up monitoring.
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